Hylaform Plus (Hylan-B gel), a large particle size hyaluronic acid-based dermal filler that is indicated for the correction of moderate to severe facial wrinkles and folds, has been granted market approval by US FDA. Hylaform Plus was developed and is manufactured by Genzyme Corporation. Inamed is Genzyme's exclusive worldwide marketing and distribution partner for Hylaform Plus.

"We are excited about the approval of Hylaform Plus, which adds to our facial aesthetic portfolio and provides new treatment options to physicians and patients in the US," said Hani Zeini, executive vice president, Inamed Aesthetics. "The approval of this important product will supply our facial business a stronger competitive offering in the US marketplace," Zeini added.

Hylaform Plus joins Inamed's US dermal filler franchise, comprised of Zyderm, Zyplast, CosmoDerm, CosmoPlast collagen and Hylaform. Hylaform Plus is a clear, colourless product that comprises a larger mean hyaluronic gel acid particle size than Hylaform.

"Hylaform Plus gel gives physicians in the US a new, effective non-surgical tool to treat the deepest wrinkles and provide optimal facial contouring," said Gary D Monheit, associate professor, Department of Dermatology, University of Alabama at Birmingham, and a Hylaform Plus US clinical trial investigator. He added, "Hylaform Plus is an excellent complement to the existing fillers available to us and is an important advancement in facial rejuvenation."

"We look forward to working with Inamed to bring Hylaform Plus to physicians and patients in the United States," Ann Merrifield, president Genzyme Biosurgery said adding, "This addition to our hyaluronic acid line will broaden the acceptance of our products among physicians by expanding their options in treating patients."